Table 1

Cohort characteristics

Identification study (plasma)Chronic pancreatitisControls
Male76%52%
Age, years (mean±SD, range)51 (±9.9, 20–73)64 (±14.5, 22–88)
BMI, kg/m² (mean±SD, range)23.1 (±4.82, 14.5–50.0)26.8 (±4.80, 17.6–42.3)
Diabetes44% (unknown in six patients)23%
% alcoholic CP: 75%
% calcifications: 45%
% PEI: 46%
% PERT: 43%
Mean disease duration, years: 13±16.91
Vascular surgery: 25%
Hernia repair: 22%
Thyroid surgery: 4%
Other: 49 %
First Validation Study (plasma)
Male83%66%
Age, years (mean±SD, range)51 (±11.5, 22–79)52 (±14.9, 24–90)
BMI, kg/m² (mean±SD, range)23.6 (±3.70, 15.7–34.8)27.3 (±5.16, 16.4–48.9)
Diabetes28%13%
% alcoholic CP: 43%
% calcifications: 68% (unknown in 29)
% PEI: 60% (unknown in 17)
% PERT: 60% (unknown in 17)
Mean disease duration, years: 7.3±8.55 (unknown in 36)
Vascular surgery: -
Hernia repair: 80%
Thyroid surgery: 20%
Other: -
Second Validation Study (serum)Blood donorsLiver cirrhosis
Male86%68%81%
Age, years (mean±SD, range)47 (±11.0, 25–71)54.6 (±11.3, 25–68)59.4 (±11.3, 28–82)
BMI, kg/m² (mean±SD, range)24.7 (±14.1, 17–34, unknown in 37)27.6 (±4.1, 20–36)28.6 (±4.1, 19–38, unknown in 32)
Diabetes12%0 %11%
% alcoholic CP: 100%
% calcifications: 16% (unknown in 34)
% PEI: 18% (unknown in 28)
% PERT: 16% (unknown in 32)
Mean disease duration, years: 1.2±1.85 (unknown in 35)
NA% alcoholic LC: 100%
  • BMI, body mass index; CP, chronic pancreatitis; LC, liver cirrhosis; NA, not applicable; PEI, pancreatic enzyme insufficiency; PERT, pancreatic enzyme replacement therapy.